Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 10/2021

01-07-2021 | Alzheimer's Disease | Leading Article

Current Status of Clinical Trials on Tau Immunotherapies

Authors: Changyi Ji, Einar M. Sigurdsson

Published in: Drugs | Issue 10/2021

Login to get access

Abstract

Tau immunotherapies have advanced from proof-of-concept studies to over a dozen clinical trials for Alzheimer’s disease (AD) and other tauopathies. Mechanistic studies in animal and culture models have provided valuable insight into how these therapies may work but multiple pathways are likely involved. Different groups have emphasized the importance of intracellular vs extracellular antibody-mediated clearance of the tau protein and there is no consensus on which pool of tau should ideally be targeted. Likewise, various normal and disease-selective epitopes are being targeted, and the antibody isotypes either favor phagocytosis of the tau-antibody complex or are neutral in that aspect. Most of the clinical trials are in early stages, thus their efficacy is not yet known, but all have been without any major adverse effects and some have reported target engagement. A few have been discontinued. One in phase I, presumably because of a poor pharmacokinetic profile, and three in phase II for a lack of efficacy although this trial stage is not well powered for efficacy measures. In these phase II studies, trials with two antibodies in patients with progressive supranuclear palsy or other primary tauopathies were halted but are continuing in patients with AD, and one antibody trial was stopped in early-stage AD but is continuing in moderate AD. These three antibodies have been reported to only work extracellularly and tau is not increased in the cerebrospinal fluid of primary tauopathies, which may explain the failures of two of them. In the discontinued AD trial, there are some concerns about how much of extracellular tau contains the N-terminal epitope that is being targeted. In addition, extracellular tau is only a small part of total tau, compared to intracellular tau. Targeting only the former may not be sufficient for functional benefits. Given these outcomes, decision makers within the pharmaceutical companies who green light these trials should attempt to target tau not only extracellularly but also intracellularly to increase their chances of success. Hopefully, some of the ongoing trials will provide some functional benefits to the large number of patients with tauopathies.
Literature
1.
2.
Pedersen JT, Sigurdsson EM. Tau immunotherapy for Alzheimer’s disease. Trends Mol Med. 2015;21(6):394–402.PubMedCrossRef
3.
4.
Arriagada PV, Growdon JH, Hedley-Whyte ET, et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology. 1992;42(3 Pt 1):631–9.PubMedCrossRef
5.
Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci. 2010;30(49):16559–66.PubMedPubMedCentralCrossRef
6.
7.
Rajamohamedsait H, Rasool S, Rajamohamedsait W, et al. Prophylactic active tau immunization leads to sustained reduction in both tau and amyloid-β pathologies in 3xTg mice. Sci Rep. 2017;7(1):17034.PubMedPubMedCentralCrossRef
8.
Wu Q, Bai Y, Li W, et al. Increased neuronal activity in motor cortex reveals prominent calcium dyshomeostasis in tauopathy mice. Neurobiol Dis. 2021;147:105165.PubMedCrossRef
9.
Sandusky-Beltran LA, Sigurdsson EM. Tau immunotherapies: lessons learned, current status and future considerations. Neuropharmacology. 2020;175:108104.PubMedCrossRefPubMedCentral
10.
Sigurdsson EM. Immunotherapy targeting pathological tau protein in Alzheimer’s disease and related tauopathies. J Alzheimers Dis. 2008;15(2):157–68.PubMedPubMedCentralCrossRef
11.
Sigurdsson EM. Alzheimer’s therapy development: a few points to consider. Prog Mol Biol Transl Sci. 2019;168:205–17.PubMedCrossRef
12.
Ittner LM, Ke YD, Delerue F, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models. Cell. 2010;142(3):387–97.CrossRefPubMed
13.
Tapia-Rojas C, Cabezas-Opazo F, Deaton CA, et al. It’s all about tau. Prog Neurobiol. 2019;175:54–76.PubMedCrossRef
14.
Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12(6):609–22.PubMedCrossRef
15.
16.
Gong CX, Liu F, Grundke-Iqbal I, et al. Post-translational modifications of tau protein in Alzheimer’s disease. J Neural Transm (Vienna). 2005;112(6):813–38.CrossRef
17.
Martin L, Latypova X, Terro F. Post-translational modifications of tau protein: implications for Alzheimer’s disease. Neurochem Int. 2011;58(4):458–71.PubMedCrossRef
18.
Grundke-Iqbal I, Iqbal K, Tung YC, et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA. 1986;83(13):4913–7.PubMedPubMedCentralCrossRef
19.
Iqbal K, Liu F, Gong CX. Tau and neurodegenerative disease: the story so far. Nat Rev Neurol. 2016;12(1):15–27.CrossRefPubMed
20.
Hoover BR, Reed MN, Su J, et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron. 2010;68(6):1067–81.PubMedPubMedCentralCrossRef
21.
Zempel H, Thies E, Mandelkow E, et al. Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous tau into dendrites, tau phosphorylation, and destruction of microtubules and spines. J Neurosci. 2010;30(36):11938–50.PubMedPubMedCentralCrossRef
22.
Xia D, Li C, Gotz J. Pseudophosphorylation of tau at distinct epitopes or the presence of the P301L mutation targets the microtubule-associated protein tau to dendritic spines. Biochim Biophys Acta. 2015;1852(5):913–24.PubMedCrossRef
23.
Li C, Gotz J. Somatodendritic accumulation of Tau in Alzheimer’s disease is promoted by Fyn-mediated local protein translation. Embo J. 2017;36(21):3120–38.PubMedPubMedCentralCrossRef
24.
Bright J, Hussain S, Dang V, et al. Human secreted tau increases amyloid-beta production. Neurobiol Aging. 2015;36(2):693–709.PubMedCrossRef
25.
26.
Yamada K, Cirrito JR, Stewart FR, et al. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci. 2011;31(37):13110–7.PubMedPubMedCentralCrossRef
27.
Holth JK, Fritschi SK, Wang C, et al. The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science. 2019;363:880–4.PubMedPubMedCentralCrossRef
28.
Chai X, Dage JL, Citron M. Constitutive secretion of tau protein by an unconventional mechanism. Neurobiol Dis. 2012;48(3):356–66.PubMedCrossRef
29.
Han P, Serrano G, Beach TG, et al. A quantitative analysis of brain soluble tau and the tau secretion factor. J Neuropathol Exp Neurol. 2017;76(1):44–51.PubMedPubMedCentral
30.
Barthelemy NR, Gabelle A, Hirtz C, et al. Differential mass spectrometry profiles of tau protein in the cerebrospinal fluid of patients with Alzheimer’s disease, progressive supranuclear palsy, and dementia with Lewy bodies. J Alzheimers Dis. 2016;51(4):1033–43.PubMedCrossRef
31.
Colin M, Dujardin S, Schraen-Maschke S, et al. From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy. Acta Neuropathol. 2020;139(1):3–25.PubMedCrossRef
32.
33.
Hales CM, Hu WT. From frontotemporal lobar degeneration pathology to frontotemporal lobar degeneration biomarkers. Int Rev Psychiatry. 2013;25(2):210–20.PubMedCrossRef
34.
Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673–84.PubMedCrossRef
35.
Sigurdsson EM. Tau immunotherapies for Alzheimer’s disease and related tauopathies: progress and potential pitfalls. J Alzheimers Dis. 2018;64(s1):S555–65.PubMedPubMedCentralCrossRef
36.
37.
Bian H, Van Swieten JC, Leight S, et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology. 2008;70(19 Pt 2):1827–35.PubMedCrossRef
38.
Grossman M, Farmer J, Leight S, et al. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease. Ann Neurol. 2005;57(5):721–9.PubMedCrossRef
39.
Wagshal D, Sankaranarayanan S, Guss V, et al. Divergent CSF τ alterations in two common tauopathies: Alzheimer’s disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2015;86(3):244–50.PubMedCrossRef
40.
Congdon EE, Chukwu JE, Shamir DB, et al. Tau antibody chimerization alters its charge and binding, thereby reducing its cellular uptake and efficacy. EBioMedicine. 2019;42:157–73.PubMedPubMedCentralCrossRef
41.
Cicognola C, Brinkmalm G, Wahlgren J, et al. Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease. Acta Neuropathol. 2019;137(2):279–96.PubMedCrossRef
42.
Meredith JE Jr, Sankaranarayanan S, Guss V, et al. Characterization of novel CSF tau and ptau biomarkers for Alzheimer’s disease. PLoS ONE. 2013;8(10):e76523.PubMedCrossRef
43.
44.
45.
46.
47.
Gerson JE, Sengupta U, Lasagna-Reeves CA, et al. Characterization of tau oligomeric seeds in progressive supranuclear palsy. Acta Neuropathol Commun. 2014;2:73.PubMedPubMedCentralCrossRef
48.
49.
Goedert M, Spillantini MG. Propagation of tau aggregates. Mol. Brain. 2017;10(1):18.
50.
51.
52.
Falcon B, Zivanov J, Zhang W, et al. Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature. 2019;568(7752):420–3.PubMedPubMedCentralCrossRef
53.
Arakhamia T, Lee CE, Carlomagno Y, et al. Posttranslational modifications mediate the structural diversity of tauopathy strains. Cell. 2020;180(4):633-44.e12.PubMedPubMedCentralCrossRef
54.
Kametani F, Yoshida M, Matsubara T, et al. Comparison of common and disease-specific post-translational modifications of pathological tau associated with a wide range of tauopathies. Front Neurosci. 2020;14:581936.PubMedPubMedCentralCrossRef
55.
56.
Congdon EE, Lin Y, Rajamohamedsait HB, et al. Affinity of tau antibodies for solubilized pathological tau species but not their immunogen or insoluble tau aggregates predicts in vivo and ex vivo efficacy. Mol Neurodegener. 2016;11(1):62.PubMedPubMedCentralCrossRef
57.
Sebastian-Serrano A, de Diego-Garcia L, Diaz-Hernandez M. The neurotoxic role of extracellular tau protein. Int J Mol Sci. 2018;19(4):998.PubMedCentralCrossRef
58.
Asuni AA, Boutajangout A, Quartermain D, et al. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci. 2007;27(34):9115–29.PubMedPubMedCentralCrossRef
59.
Congdon EE, Gu J, Sait HB, et al. Antibody uptake into neurons occurs primarily via clathrin-dependent Fcgamma receptor endocytosis and is a prerequisite for acute tau protein clearance. J Biol Chem. 2013;288(49):35452–65.PubMedPubMedCentralCrossRef
60.
Gu J, Congdon EE, Sigurdsson EM. Two novel tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce tau protein pathology. J Biol Chem. 2013;288(46):33081–95.PubMedPubMedCentralCrossRef
61.
Krishnamurthy PK, Deng Y, Sigurdsson EM. Mechanistic studies of antibody-mediated clearance of tau aggregates using an ex vivo brain slice model. Front Psychiatry. 2011;2:59.PubMedPubMedCentralCrossRef
62.
63.
Shamir DB, Deng Y, Sigurdsson EM. Live imaging of pathological tau protein and tau antibodies in a neuron-like cellular model. Methods Mol Biol. 2018;1779:371–9.PubMedCrossRef
64.
Shamir DB, Deng Y, Wu Q, et al. Dynamics of internalization and intracellular interaction of tau antibodies and human pathological tau protein in a human neuron-like model. Front Neurol. 2020;11:602292.PubMedPubMedCentralCrossRef
65.
Shamir DB, Rosenqvist N, Rasool S, et al. Internalization of tau antibody and pathological tau protein detected with a flow cytometry multiplexing approach. Alzheimers Dement. 2016;12(10):1098–107.PubMedPubMedCentralCrossRef
66.
Wu Q, Lin Y, Gu J, et al. Dynamic assessment of tau immunotherapies in the brains of live animals by two-photon imaging. EBioMedicine. 2018;35:270–8.PubMedPubMedCentralCrossRef
67.
Collin L, Bohrmann B, Gopfert U, et al. Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer’s disease. Brain. 2014;137(Pt 10):2834–46.PubMedCrossRef
68.
Yanamandra K, Jiang H, Mahan TE, et al. Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann Clin Transl Neurol. 2015;2(3):278–88.PubMedPubMedCentralCrossRef
69.
Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, et al. Passive immunization with tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci. 2014;34(12):4260–72.PubMedPubMedCentralCrossRef
70.
d’Abramo C, Acker CM, Jimenez H, et al. Passive Immunization in JNPL3 transgenic mice using an array of phospho-tau specific antibodies. PLoS ONE. 2015;10(8):e0135774.PubMedPubMedCentralCrossRef
71.
72.
Andersson CR, Falsig J, Stavenhagen JB, et al. Antibody-mediated clearance of tau in primary mouse microglial cultures requires Fcγ-receptor binding and functional lysosomes. Sci Rep. 2019;9(1):4658.PubMedPubMedCentralCrossRef
73.
Funk KE, Mirbaha H, Jiang H, et al. Distinct therapeutic mechanisms of tau antibodies: promoting microglial clearance versus blocking neuronal uptake. J Biol Chem. 2015;290(35):21652–62.PubMedPubMedCentralCrossRef
74.
Luo W, Liu W, Hu X, et al. Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody. Sci Rep. 2015;5:11161.PubMedPubMedCentralCrossRef
75.
Castillo-Carranza DL, Gerson JE, Sengupta U, et al. Specific targeting of tau oligomers in tau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds. J Alzheimers Dis. 2014;40(Suppl. 1):S97-111.PubMedCrossRef
76.
Chai X, Wu S, Murray TK, et al. Passive immunization with anti-tau antibodies in two transgenic models: reduction of tau pathology and delay of disease progression. J Biol Chem. 2011;286(39):34457–67.PubMedPubMedCentralCrossRef
77.
Dai CL, Chen X, Kazim SF, et al. Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies. J Neural Transm (Vienna). 2015;122(4):607–17.CrossRef
78.
79.
Davtyan H, Chen WW, Zagorski K, et al. MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice. Vaccine. 2017;35(16):2015–24.PubMedPubMedCentralCrossRef
80.
Kondo A, Shahpasand K, Mannix R, et al. Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature. 2015;523(7561):431–6.PubMedPubMedCentralCrossRef
81.
Nobuhara CK, DeVos SL, Commins C, et al. Tau antibody targeting pathological species blocks neuronal uptake and interneuron propagation of tau in vitro. Am J Pathol. 2017;187(6):1399–412.PubMedPubMedCentralCrossRef
82.
Sankaranarayanan S, Barten DM, Vana L, et al. Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models. PLoS ONE. 2015;10(5):e0125614.PubMedPubMedCentralCrossRef
83.
Subramanian S, Savanur G, Madhavadas S. Passive immunization targeting the N-terminal region of phosphorylated tau (residues 68–71) improves spatial memory in okadaic acid induced tauopathy model rats. Biochem Biophys Res Commun. 2017;483(1):585–9.PubMedCrossRef
84.
Troquier L, Caillierez R, Burnouf S, et al. Targeting phospho-Ser422 by active tau immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res. 2012;9(4):397–405.PubMedPubMedCentralCrossRef
85.
Umeda T, Eguchi H, Kunori Y, et al. Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice. Ann Clin Transl Neurol. 2015;2(3):241–55.PubMedPubMedCentralCrossRef
86.
87.
Yanamandra K, Kfoury N, Jiang H, et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80(2):402–14.PubMedPubMedCentralCrossRef
88.
Yanamandra K, Patel TK, Jiang H, et al. Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. Sci Transl Med. 2017;9(386):eaal2029.PubMedPubMedCentralCrossRef
89.
Modak SR, Sigurdsson EM. Antibodies targeting truncated Asp421 tau protein clear human Alzheimer’s tau and prevent its toxicity in primary neuronal and mixed cortical cultures. Soc Neurosci Abstract. 2017; p. 478.19.
90.
Modak SR, Solesio M, Krishnaswamy S, et al. Antibodies targeting truncated tau protein reduce tau pathology in primary and mixed cortical cultures. Soc Neurosci Abstract. 2015; p. 579.14.
91.
Bi M, Ittner A, Ke YD, et al. Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS ONE. 2011;6(12):e26860.PubMedPubMedCentralCrossRef
92.
Ittner A, Bertz J, Suh LS, et al. Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice. J Neurochem. 2015;132(1):135–45.PubMedCrossRef
93.
Liu W, Zhao L, Blackman B, et al. Vectored intracerebral immunization with the anti-tau monoclonal antibody PHF1 markedly reduces tau pathology in mutant tau transgenic mice. J Neurosci. 2016;36(49):12425–35.PubMedPubMedCentralCrossRef
94.
Rosenqvist N, Asuni AA, Andersson CR, et al. Highly specific and selective anti-pS396-tau antibody C10.2 targets seeding-competent tau. Alzheimers Dement (N Y). 2018;4:521–34.CrossRef
95.
Theunis C, Crespo-Biel N, Gafner V, et al. Efficacy and safety of a liposome-based vaccine against protein tau, assessed in tau.P301L mice that model tauopathy. PLoS ONE. 2013;8(8):e72301.PubMedPubMedCentralCrossRef
96.
Agadjanyan MG, Zagorski K, Petrushina I, et al. Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency. Mol Neurodegener. 2017;12(1):33.PubMedPubMedCentralCrossRef
97.
Albert M, Mairet-Coello G, Danis C, et al. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody. Brain. 2019;142(6):1736–50.PubMedPubMedCentralCrossRef
98.
Courade JP, Angers R, Mairet-Coello G, et al. Epitope determines efficacy of therapeutic anti-tau antibodies in a functional assay with human Alzheimer tau. Acta Neuropathol. 2018;136(5):729–45.PubMedPubMedCentralCrossRef
99.
Kontsekova E, Zilka N, Kovacech B, et al. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model. Alzheimers Res Ther. 2014;6(4):44.PubMedPubMedCentralCrossRef
100.
101.
102.
103.
Andoh T, Kuraishi Y. Direct action of immunoglobulin G on primary sensory neurons through Fc gamma receptor I. FASEB J. 2004;18(1):182–4.PubMedCrossRef
104.
Fernandez-Vizarra P, Lopez-Franco O, Mallavia B, et al. Immunoglobulin G Fc receptor deficiency prevents Alzheimer-like pathology and cognitive impairment in mice. Brain. 2012;135(Pt 9):2826–37.PubMedCrossRef
105.
Suemitsu S, Watanabe M, Yokobayashi E, et al. Fcgamma receptors contribute to pyramidal cell death in the mouse hippocampus following local kainic acid injection. Neuroscience. 2010;166(3):819–31.PubMedCrossRef
106.
van der Kleij H, Charles N, Karimi K, et al. Evidence for neuronal expression of functional Fc (epsilon and gamma) receptors. J Allergy Clin Immunol. 2010;125(3):757–60.PubMedPubMedCentralCrossRef
107.
Lee SH, Le Pichon CE, Adolfsson O, et al. Antibody-mediated targeting of tau in vivo does not require effector function and microglial engagement. Cell Rep. 2016;16(6):1690–700.PubMedCrossRef
108.
Boutajangout A, Ingadottir J, Davies P, et al. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem. 2011;118(4):658–67.PubMedPubMedCentralCrossRef
109.
d’Abramo C, Acker CM, Jimenez HT, et al. Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. PLoS ONE. 2013;8(4):e62402.PubMedPubMedCentralCrossRef
110.
Jicha GA, Bowser R, Kazam IG, et al. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res. 1997;48(2):128–32.PubMedCrossRef
111.
Krishnaswamy S, Wu Q, Lin Y, et al. In vivo imaging of tauopathy in mice. Methods Mol Biol. 2018;1779:513–26.PubMedCrossRef
112.
Krishnaswamy S, Huang HW, Marchal IS, et al. Neuronally expressed anti-tau scFv prevents tauopathy-induced phenotypes in Drosophila models. Neurobiol Dis. 2020;137:104770.PubMedPubMedCentralCrossRef
113.
Ising C, Gallardo G, Leyns CEG, et al. AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy. J Exp Med. 2017;214(5):1227–38.PubMedPubMedCentralCrossRef
114.
Nisbet RM, Van der Jeugd A, Leinenga G, et al. Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model. Brain. 2017;140(5):1220–30.PubMedPubMedCentralCrossRef
115.
Spencer B, Bruschweiler S, Sealey-Cardona M, et al. Selective targeting of 3 repeat tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders. Acta Neuropathol. 2018;136(1):69–87.PubMedPubMedCentralCrossRef
116.
Vitale F, Giliberto L, Ruiz S, et al. Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice. Acta Neuropathol Commun. 2018;6(1):82.PubMedPubMedCentralCrossRef
117.
118.
Goodwin MS, Sinyavskaya O, Burg F, et al. Anti-tau scFvs targeted to the cytoplasm or secretory pathway variably modify pathology and neurodegenerative phenotypes. Mol Ther. 2021;29(2):859–72.PubMedCrossRef
119.
Dupre E, Danis C, Arrial A, et al. Single domain antibody fragments as new tools for the detection of neuronal tau protein in cells and in mice studies. ACS Chem Neurosci. 2019;10(9):3997–4006.PubMedCrossRef
120.
Li T, Vandesquille M, Koukouli F, et al. Camelid single-domain antibodies: a versatile tool for in vivo imaging of extracellular and intracellular brain targets. J Control Release. 2016;243:1–10.PubMedCrossRef
121.
Congdon EE, Lin Y, Sigurdsson EM. Prevention of intra- and extracellular alpha-synuclein toxicity and seeding by single domain antibodies. Soc Neurosci Abstract. 2019; p. 537.07.
122.
Marchal IS, Huang HW, Krishnaswamy S, et al. Neuronally expressed anti-tau scFvs and sdAbs prevent tauopathy-induced phenotypes in Drosophila models. Soc Neurosci Abstract. 2019; p. 446.12.
123.
Sandusky-Beltran LA, Congdon EE, Modak SR, et al. Examining the impact of single domain anti-tau immunotherapies in an animal model of tauopathy. Alzheimer’s Disease & Parkinson’s disease (ADPD) Conference. In: Abstract. 2019;Symposium 14:Treatment of Tauopathies.
124.
Novak P, Schmidt R, Kontsekova E, et al. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol. 2017;16(2):123–34.PubMedCrossRef
125.
Novak P, Schmidt R, Kontsekova E, et al. FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease. Alzheimers Res Ther. 2018;10(1):108.PubMedPubMedCentralCrossRef
126.
127.
128.
Hickman DT, Lopez-Deber MP, Ndao DM, et al. Sequence-independent control of peptide conformation in liposomal vaccines for targeting protein misfolding diseases. J Biol Chem. 2011;286(16):13966–76.PubMedPubMedCentralCrossRef
129.
130.
131.
132.
133.
134.
Czerkowicz J, Chen W, Wang Q, et al. Pan-tau antibody BIIB076 exhibits promising safety and biomarker profile in cynomolgus monkey toxicity study. Alzheimers Dement. 2017;13(7):P1271.
135.
136.
Sopko R, Golonzhka O, Arndt J, et al. Characterization of tau binding by gosuranemab. Neurobiol Dis. 2020;146:105120.PubMedCrossRef
137.
Qureshi IA, Tirucherai G, Ahlijanian MK, et al. A randomized, single ascending dose study of intravenous BIIB092 in healthy participants. Alzheimers Dement (N Y). 2018;4:746–55.CrossRef
138.
Boxer AL, Qureshi I, Ahlijanian M, et al. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol. 2019;18(6):549–58.PubMedCrossRef
139.
140.
141.
142.
143.
144.
West T, Hu Y, Verghese PB, et al. Preclinical and clinical development of ABBV-8E12, a humanized anti-tau antibody, for treatment of Alzheimer’s disease and other tauopathies. J Prev Alzheimers Dis. 2017;4(4):236–41.PubMed
145.
146.
Höglinger GU, Litvan I, Mendonca N, et al. Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet Neurol. 2021;20(3):182–92.PubMedCrossRef
147.
Roberts M, Sevastou I, Imaizumi Y, et al. Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer’s disease. Acta Neuropathol Commun. 2020;8(1):13.PubMedPubMedCentralCrossRef
148.
Eisai presents data showing quantification of tau microtubule binding region in cerebrospinal fluid and the identification of a target engagement biomarker for the new anti-tau antibody e2814 at Alzheimer’s Association International Conference (AAIC) 2019. July 19, 2019 [press release]. https://​www.​eisai.​com/​news/​2019/​news201955.​html. Accessed 19 May 2021.
149.
Horie K, Barthélemy NR, Sato C, et al. CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer’s disease. Brain. 2021;144(2):515–27.PubMedCrossRef
150.
Horie K, Takahashi E, Aoyama M, et al. Quantification of the tau microtubule binding region (Mtbr) in cerebrospinal fluid and subsequent validation of target engagement assay for E2814, a novel anti-tau therapeutic antibody. In: Alzheimer's Association International Conference; July 2019: p. P4–696.
151.
152.
Alam R, Driver D, Wu S, et al. Preclinical characterization of an antibody [Ly3303560] targeting aggregated tau. Alzheimers Dement. 2017;13(7):P592–3.
153.
154.
Galpern WR, Mercken M, Kolen KV, et al. P1–052: A single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-phospho-tau antibody JNJ-63733657 in healthy subjects. Alzheimers Dement. 2019;15(7S):252–3.CrossRef
155.
156.
Buchanan T, De Bruyn S, Fadini T, et al. A randomised, placebo-controlled, first-inhuman study with a central Tau epitope antibody: UCB0107. In: International Congress of Parkinson’s Disease and Movement Disorders; 2019 Late-Breaking Abstracts. 2019; p. LBA3.
157.
Naserkhaki R, Zamanzadeh S, Baharvand H, et al. cis pT231-tau drives neurodegeneration in bipolar disorder. ACS Chem Neurosci. 2019;10(3):1214–21.PubMedCrossRef
158.
Albayram O, Kondo A, Mannix R, et al. Cis P-tau is induced in clinical and preclinical brain injury and contributes to post-injury sequelae. Nat Commun. 2017;8(1):1000.PubMedPubMedCentralCrossRef
159.
160.
161.
162.
Kerchner GA, Ayalon G, Brunstein F, et al. A phase I study to evaluate the safety and tolerability of RO7105705 in healthy volunteers and patients with mild-to-moderate AD. Alzheimers Dement. 2017;13(7):P601.
163.
Metadata
Title
Current Status of Clinical Trials on Tau Immunotherapies
Authors
Changyi Ji
Einar M. Sigurdsson
Publication date
01-07-2021
Publisher
Springer International Publishing
Published in
Drugs / Issue 10/2021
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-021-01546-6

Other articles of this Issue 10/2021

Drugs 10/2021 Go to the issue

AdisInsight Report

Dostarlimab: First Approval

Review Article

Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions

Correction

Correction to: Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC

Letter to the Editor

Post-COVID-19 Syndrome: Leveraging the Patient Perspective and Technological Innovations to Enable the Delineation of Effective Treatments

Adis Drug Evaluation

Bupivacaine/Meloxicam Prolonged Release: A Review in Postoperative Pain

Correction

Correction to: Fuzuloparib: First Approval